8th January 2004Our new unit at St George's Hospital is open for businessThe opening of our second unit makes Richmond Pharmacology the largest phase I CRO in the UK. Our total capacity across the two sites has increased to 90 beds.The new unit is located in the Knightsbridge Wing of St George’s Hospital, Tooting, London. Situated within refurbished, access-controlled facilities and run by the same dedicated and highly trained team of over 80 staff already working at our Atkinson Morley’s Hospital Unit.We have made a further significant investment in our state of the art equipment with networked 12 lead Marquette ECGs at every bed.St George’s Healthcare Trust is one of the largest and busiest National Health Service Trusts in the country. As well as providing general and acute services, the hospital offers a range of specialist, teaching and research facilities with links to the services of St Georges Hospital Medical School.St George’s Hospital Medical School. The even closer proximity to the Medical School provides further opportunities for joint academic research, specialist studies or patient trials.Richmond Pharmacology’s new unit is one of the only commercial Phase I CROs with facilities located within the same site as both the Teaching Hospital and Medical School.To request a brochure on our new facilities or to arrange a site visit please contact Claire Tucker today.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event